Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 315

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

Open access
Vrooman, Lynda M., Stevenson, Kristen E., Supko, Jeffrey G., O'Brien, Jane, Dahlberg, Suzanne E., Asselin, Barbara L., Athale, Uma H., Clavell, Luis A., Kelly, Kara M., Kutok, Jeffery L., Laverdière, Caroline, Lipshultz, Steven E., Michon, Bruno, Schorin, Marshall, Relling, Mary V., Cohen, Harvey J., Neuberg, Donna S., Sallan, Stephen E., Silverman, Lewis B. · 2013 · Journal of Clinical Oncology

Abstract

Purpose: We assessed the toxicity and efficacy of dexamethasone and a novel dosing method of Escherichia coli L-asparaginase (EC-Asnase) in children and adolescents with newly diagnosed acute lymphoblastic leukemia (ALL). Patients and Methods: Patients achieving complete remission (CR) on Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 were eligible for random assignment to 1) dexamethasone or prednisone, administered as 5-day pulses, every 3 weeks, and 2) weekly EC-Asnase, administered as a 25,000 IU/m 2 fixed dose (FD) or individualized dose (ID) starting at 12,500-IU/m 2 , adjusted every 3 weeks based on nadir serum asparaginase activity (NSAA) determinations. Results: Between 2000 and 2004, 492 evaluable patients (ages 1 to 18 years) enrolled; 473 patients (96%) achieved CR. Four hundred eight patients (86%) participated in the corticosteroid randomization and 384 patients (81%) in the EC-Asnase randomization. With 4.9 years of median follow-up, dexamethasone was associated with superior 5-year event-free survival (EFS; 90% v 81% for prednisone; P = .01) but higher rates of infection (P = .03) and, in older children, higher cumulative incidence of osteonecrosis (P = .02) and fracture (P = .06). ID EC-Asnase had superior 5-year EFS (90% v 82% for FD; P = .04), but did not reduce the frequency of asparaginase-related toxicity. Multivariable analysis identified both dexamethasone and ID EC-Asnase as independent predictors of favorable EFS. Conclusion: There was no overall difference in skeletal toxicity by corticosteroid type; dexamethasone was associated with more infections and, in older children, increased incidence of osteonecrosis and fracture. There was no difference in asparaginase-related toxicity by EC-Asnase dosing method. Dexamethasone and ID EC-Asnase were each associated with superior EFS. Monitoring NSAA during treatment with EC-Asnase may be an effective strategy to improve outcome in pediatric ALL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.43.2070

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 315

Metadata

Authors
Vrooman, L. M., Stevenson, K. E., Supko, J. G., O'Brien, J., Dahlberg, S. E., Asselin, B. L., Athale, U. H., Clavell, L. A., Kelly, K. M., Kutok, J. L., Laverdière, C., Lipshultz, S. E., Michon, B., Schorin, M., Relling, M. V., Cohen, H. J., Neuberg, D. S., Sallan, S. E., & Silverman, L. B.
Venue
Journal of Clinical Oncology
Published
2013-03-20
Volume
31
Issue
9
Pages
1202-1210
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2169732420
Cited by
315
References
24
FWCI
30.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. https://app.cochat.ai/papers/10.1200/jco.2012.43.2070
The paper
Vrooman, L. M., Stevenson, K. E., Supko, J. G., O'Brien, J., Dahlberg, S. E., Asselin, B. L., Athale, U. H., Clavell, L. A., Kelly, K. M., Kutok, J. L., Laverdière, C., Lipshultz, S. E., Michon, B., Schorin, M., Relling, M. V., Cohen, H. J., Neuberg, D. S., Sallan, S. E., & Silverman, L. B. (2013). Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.43.2070

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.